Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alaunos Therapeutics Inc

TCRT ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.04

▼ -1.30%

Market Cap $10.99M · Vol 146.38K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.99M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

73.03

Momentum

Beta

-0.73

vs Market

52W High

$4.49

31.40% below

52W Low

$0.72

324.89% above

Volume

146.38K

Avg 1.11M

P/B

3.52

Price-to-book

ROE

N/A

Return on equity

Free Float

87.59%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Alaunos Therapeutics Inc (TCRT) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TCRT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+39.45%

+139.37%

+52.00%

+11.36%

YTD

-5.88%

+18.75%

-81.59%

-98.72%

Financials & Valuation

TTM · Annual

Total Revenue	$5.00K
Net Income	$-4,176,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-84,500.00%
Net Profit Margin	-83,520.00%
ROE	N/A
ROA · ROIC	-145.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1,258.64
P/B	3.52
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.61M

Technical Indicators

50-Day SMA	$1.61
200-Day SMA	$2.36
RSI (14)	73.03
Beta	-0.73
52-Week High	$4.49
52-Week Low	$0.72

Volume Today	146.38K
Avg Daily Volume (30D)	1.11M
Relative Volume	0.13x
Volatility (10D)	556.79
Volatility (30D)	367.44
Free Float	87.59%

Analyst Consensus

N/A

Current Price $3.04

Mean Target N/A

52W Low$0.72 52W High$4.49

Current

Target

$0.72 $4.49

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SM7BJ6

ISINUS98973P3091

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.